Literature DB >> 18726585

Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause.

R Taylor1.   

Abstract

The metabolic abnormalities of type 2 diabetes can be reversed reproducibly by bariatric surgery. By quantifying the major pathophysiological abnormalities in insulin secretion and insulin action after surgery, the sequence of events leading to restoration of normal metabolism can be defined. Liver fat levels fall within days and normal hepatic insulin sensitivity is restored. Simultaneously, plasma glucose levels return towards normal. Insulin sensitivity of muscle remains abnormal, at least over the weeks and months after bariatric surgery. The effect of the surgery is explicable solely in terms of energy restriction. By combining this information with prospective observation of the changes immediately preceding the onset of type 2 diabetes, a clear picture emerges. Insulin resistance in muscle, caused by inherited and environmental factors, facilitates the development of fatty liver during positive energy balance. Once established, the increased insulin secretion required to maintain plasma glucose levels will further increase liver fat deposition. Fatty liver causes resistance to insulin suppression of hepatic glucose output as well as raised plasma triacylglycerol. Exposure of beta cells to increased levels of fatty acids, derived from circulating and locally deposited triacylglycerol, suppresses glucose-mediated insulin secretion. This is reversible initially, but eventually becomes permanent. The essential time sequence of the pathogenesis of type 2 diabetes is now evident. Muscle insulin resistance determines the rate at which fatty liver progresses, and ectopic fat deposition in liver and islet underlies the related dynamic defects of hepatic insulin resistance and beta cell dysfunction. These defects are capable of dramatic reversal under hypoenergetic feeding conditions, completely in early diabetes and to a worthwhile extent in more established disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726585     DOI: 10.1007/s00125-008-1116-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  45 in total

1.  Chronological development of elevated aminotransferases in a nonalcoholic population.

Authors:  Ayako Suzuki; Paul Angulo; James Lymp; Jennifer St Sauver; Ayako Muto; Toshihide Okada; Keith Lindor
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery.

Authors:  Stefania Camastra; Melania Manco; Andrea Mari; Aldo V Greco; Silvia Frascerra; Geltrude Mingrone; Ele Ferrannini
Journal:  Diabetes Care       Date:  2007-04       Impact factor: 19.112

4.  NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice.

Authors:  Valerio Nobili; Matilde Marcellini; Rita Devito; Paolo Ciampalini; Fiorella Piemonte; Donatella Comparcola; Maria Rita Sartorelli; Paul Angulo
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

5.  Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease.

Authors:  Gianluca Perseghin; Riccardo Bonfanti; Serena Magni; Guido Lattuada; Francesco De Cobelli; Tamara Canu; Antonio Esposito; Paola Scifo; Georgia Ntali; Federica Costantino; Laura Bosio; Francesca Ragogna; Alessandro Del Maschio; Giuseppe Chiumello; Livio Luzi
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-05-09       Impact factor: 4.310

6.  Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity.

Authors:  R Firth; P Bell; R Rizza
Journal:  Metabolism       Date:  1987-11       Impact factor: 8.694

7.  Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria.

Authors:  L S Sidossis; C A Stuart; G I Shulman; G D Lopaschuk; R R Wolfe
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

8.  Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue.

Authors:  Anne Boucher; Danhong Lu; Shawn C Burgess; Sabine Telemaque-Potts; Mette V Jensen; Hindrik Mulder; May-Yun Wang; Roger H Unger; A Dean Sherry; Christopher B Newgard
Journal:  J Biol Chem       Date:  2004-04-07       Impact factor: 5.157

9.  Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets.

Authors:  Jean-Marc Schwarz; Peter Linfoot; Doris Dare; Karmen Aghajanian
Journal:  Am J Clin Nutr       Date:  2003-01       Impact factor: 7.045

10.  Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor.

Authors:  Naveed Sattar; Alex McConnachie; Ian Ford; Allan Gaw; Stephen J Cleland; Nita G Forouhi; Peter McFarlane; James Shepherd; Stuart Cobbe; Chris Packard
Journal:  Diabetes       Date:  2007-04       Impact factor: 9.461

View more
  80 in total

Review 1.  The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives.

Authors:  Lei Chen; Dianna J Magliano; Paul Z Zimmet
Journal:  Nat Rev Endocrinol       Date:  2011-11-08       Impact factor: 43.330

Review 2.  The Role of the Vagal Nucleus Tractus Solitarius in the Therapeutic Effects of Obesity Surgery and Other Interventional Therapies on Type 2 Diabetes.

Authors:  Claudio Blasi
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

Review 3.  Calorie restriction for long-term remission of type 2 diabetes.

Authors:  Roy Taylor
Journal:  Clin Med (Lond)       Date:  2019-01       Impact factor: 2.659

4.  Laparoscopic Sleeve Gastrectomy Versus Banded Roux-en-Y Gastric Bypass for Diabetes and Obesity: a Prospective Randomised Double-Blind Trial.

Authors:  Rinki Murphy; Michael G Clarke; Nicholas J Evennett; S John Robinson; M Lee Humphreys; Hisham Hammodat; Bronwen Jones; David D Kim; Richard Cutfield; Malcolm H Johnson; Lindsay D Plank; Michael W C Booth
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

5.  Type 2 diabetes, bariatric surgery and the risk of subsequent gestational diabetes.

Authors:  S Steven; S Woodcock; P K Small; R Taylor
Journal:  Obstet Med       Date:  2011-09-15

Review 6.  Gestational diabetes: emerging concepts in pathophysiology.

Authors:  Kenneth Hodson; Stephen Robson; Roy Taylor
Journal:  Obstet Med       Date:  2010-12-03

7.  Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Geraldine J Ooi; Paul R Burton; Lisa Doyle; John M Wentworth; Prithi S Bhathal; Ken Sikaris; Michael A Cowley; Stuart K Roberts; William Kemp; Arul Earnest; Paul E O'Brien; Wendy A Brown
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

Review 8.  Exercise therapy in type 2 diabetes.

Authors:  Stephan F E Praet; Luc J C van Loon
Journal:  Acta Diabetol       Date:  2009-05-29       Impact factor: 4.280

9.  Low-fat versus low-carbohydrate weight reduction diets: effects on weight loss, insulin resistance, and cardiovascular risk: a randomized control trial.

Authors:  Una Bradley; Michelle Spence; C Hamish Courtney; Michelle C McKinley; Cieran N Ennis; David R McCance; Jane McEneny; Patrick M Bell; Ian S Young; Steven J Hunter
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

Review 10.  The environment within: how gut microbiota may influence metabolism and body composition.

Authors:  A Vrieze; F Holleman; E G Zoetendal; W M de Vos; J B L Hoekstra; M Nieuwdorp
Journal:  Diabetologia       Date:  2010-01-26       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.